Abbott Laboratories 将来の成長

Future 基準チェック /46

Abbott Laboratories利益と収益がそれぞれ年間11.6%と6.7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に22% 11.8%なると予測されています。

主要情報

11.6%

収益成長率

11.8%

EPS成長率

Medical Equipment 収益成長	18.8%
収益成長率	6.7%
将来の株主資本利益率	22.0%
アナリストカバレッジ	Good
最終更新日	19 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

WBAG:ABT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	48,267	7,805	9,344	11,508	23
12/31/2025	44,976	6,851	8,892	10,810	25
12/31/2024	41,998	5,938	9,105	11,006	25
9/30/2024	41,217	5,744	6,486	8,728	N/A
6/30/2024	40,725	5,535	5,654	7,900	N/A
3/31/2024	40,326	5,608	4,923	7,143	N/A
12/31/2023	40,109	5,701	5,059	7,261	N/A
9/30/2023	39,959	5,142	4,492	6,549	N/A
6/30/2023	40,226	5,140	5,488	7,452	N/A
3/31/2023	41,505	5,785	6,823	8,659	N/A
12/31/2022	43,653	6,905	7,804	9,581	N/A
9/30/2022	45,030	7,857	8,541	10,322	N/A
6/30/2022	45,548	8,520	8,468	10,243	N/A
3/31/2022	44,514	7,695	8,152	9,961	N/A
12/31/2021	43,075	7,042	8,648	10,533	N/A
9/30/2021	42,308	7,208	9,314	11,264	N/A
6/30/2021	40,233	6,343	8,644	10,629	N/A
3/31/2021	37,338	5,693	7,609	9,823	N/A
12/31/2020	34,608	4,449	5,724	7,901	N/A
9/30/2020	32,221	3,346	4,587	6,519	N/A
6/30/2020	31,444	3,073	4,564	6,401	N/A
3/31/2020	32,095	3,539	4,476	6,139	N/A
12/31/2019	31,904	3,666	4,498	6,136	N/A
9/30/2019	31,355	3,272	3,814	5,485	N/A
6/30/2019	30,935	2,867	4,096	5,720	N/A
3/31/2019	30,723	2,582	4,450	5,904	N/A
12/31/2018	30,578	2,319	4,906	6,300	N/A
9/30/2018	30,402	802	4,903	6,175	N/A
6/30/2018	29,575	812	N/A	5,997	N/A
3/31/2018	28,445	365	N/A	6,104	N/A
12/31/2017	27,390	344	N/A	5,570	N/A
9/30/2017	25,134	1,971	N/A	5,100	N/A
6/30/2017	23,607	1,055	N/A	4,312	N/A
3/31/2017	22,303	1,384	N/A	3,870	N/A
12/31/2016	20,853	1,056	N/A	3,203	N/A
9/30/2016	20,708	989	N/A	2,861	N/A
6/30/2016	20,556	1,939	N/A	2,839	N/A
3/31/2016	20,393	2,124	N/A	2,871	N/A
12/31/2015	20,405	2,586	N/A	2,966	N/A
9/30/2015	20,573	2,523	N/A	3,376	N/A
6/30/2015	20,502	2,365	N/A	3,382	N/A
3/31/2015	20,389	2,004	N/A	3,341	N/A
12/31/2014	20,247	1,710	N/A	3,675	N/A
9/30/2014	19,905	1,560	N/A	4,062	N/A
6/30/2014	19,651	1,762	N/A	3,383	N/A
3/31/2014	19,034	1,654	N/A	3,200	N/A
12/31/2013	19,657	1,970	N/A	3,324	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ABTの予測収益成長率 (年間11.6% ) は貯蓄率 ( 1.4% ) を上回っています。

収益対市場: ABTの収益 ( 11.6% ) はAustrian市場 ( 9.1% ) よりも速いペースで成長すると予測されています。

高成長収益: ABTの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: ABTの収益 ( 6.7% ) Austrian市場 ( 0.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: ABTの収益 ( 6.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ABTの自己資本利益率は、3年後には高くなると予測されています ( 22 %)

Abbott Laboratories 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Abbott Laboratories Provides Earnings Guidance for the Third-Quarter 2024

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Recent updates

Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure

Third quarter 2024 earnings released: EPS: US$0.94 (vs US$0.82 in 3Q 2023)

Abbott Laboratories (NYSE:ABT) announces an Equity Buyback for $7,000 million worth of its shares.

Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping

Upcoming dividend of US$0.55 per share

Abbott Laboratories to Report Q3, 2024 Results on Oct 16, 2024

Second quarter dividend of US$0.55 announced

Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression

Second quarter 2024 earnings released: EPS: US$0.74 (vs US$0.79 in 2Q 2023)

Abbott Laboratories Provides Earnings Guidance for the Third-Quarter 2024

Upcoming dividend of US$0.55 per share

Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth-Defensive Index

Abbott Laboratories to Report Q2, 2024 Results on Jul 18, 2024

Purchasers of Certain PediaSure Products in California May Have Their Rights Affected by a Class Action Lawsuit

First quarter dividend of US$0.55 announced

Abbott Teams Up with the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health

Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2024

Insider recently sold €2.3m worth of stock

First quarter 2024 earnings released: EPS: US$0.70 (vs US$0.76 in 1Q 2023)

First quarter 2024 earnings released: EPS: US$0.70 (vs US$0.75 in 1Q 2023)

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Upcoming dividend of US$0.55 per share

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Abbott Receives FDA Approval for Triclip™, First-Of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2024 Results on Apr 17, 2024

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Announces Real-World Data Show Freestyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Fourth quarter dividend of US$0.55 announced

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve

Abbott Laboratories Announces the Launch of Its New PROTALITY Brand

Abbott Launches Smallest Rechargeable System with Remote Programming Capabilities to Treat Movement Disorders

Now 20% overvalued after recent price rise

Full year 2023 earnings released: EPS: US$3.27 (vs US$3.94 in FY 2022)

Abbott Laboratories Provides Earnings Guidance for the Full Year 2024

Abbott Laboratories Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott Laboratories Announces Quarterly Dividend Payable on Feb. 15, 2024

Abbott Announces New Late-Breaking Data That Show Advanced Heart Failure Patients Living with its HeartMate 3 Heart Pump

Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes

Now 20% undervalued after recent price drop

Abbott Laboratories Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

Independent Director recently sold €4.5m worth of stock

Abbott Announces Late-Breaking Data from the LIFE-BTK Clinical Trial Evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

Third quarter 2023 earnings released: EPS: US$0.82 (vs US$0.81 in 3Q 2022)

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Upcoming dividend of US$0.51 per share at 2.1% yield

Now 21% undervalued after recent price drop

Abbott Laboratories to Report Q3, 2023 Results on Oct 18, 2023

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘